Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 588 • 2015 ACR/ARHP Annual Meeting
Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance
Jun Kikuchi, Akiko Shibata, Ryota Sakai, Kentaro Chino, Tsuneo Kondo, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Tocilizumab (TCZ) is clinically effective against rheumatoid arthritis (RA) and over 50% of RA patients who had completed 5 years of TCZ treatment maintained…
Abstract Number: 593 • 2015 ACR/ARHP Annual Meeting
Predicting the Need for Additional Treatment in Early Rheumatoid Arthritis Patients Treated to Target on Methotrexate Monotherapy
Xavier Teitsma¹, Johannes Jacobs², Paco Welsing³, Thasia Woodworth⁴, Attila Pethö-Schramm⁵, Michelle Borm⁶, Corrado Bernasconi⁵, Floris Lafeber¹ and Johannes W J Bijlsma⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department Rheumatology and clinical immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ⁵F. Hoffmann-La Roche, Basel, Switzerland, ⁶Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Joint damage and functional disability can be reduced by intensive treatment of newly diagnosed rheumatoid arthritis (RA) patients during the "window of opportunity". Although…
Abstract Number: 600 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Disease Activity in Rheumatoid Arthritis
Virginia Ruiz-Esquide¹, Pascal Zufferey², Jose Inciarte-Mundo¹, Jordi Yagüe³, M. Victoria Hernández⁴, Julio Ramirez¹, Jeanne Berner², Mariona Pascal³, Andrea Cuervo¹, Juan D. Cañete⁵ and Raimon Sanmarti^1,6, ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³Immunology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Hospital Clínic i Provincial, Barcelona, Spain, ⁵Arthritis Unit, Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁶Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6R monoclonal antibody approved for the treatment of active rheumatoid arthritis (RA) (EMA: 8mg/kg q4w). Response to treatment may…
Abstract Number: 613 • 2015 ACR/ARHP Annual Meeting
Correlation Between Efficacy of Tocilizumab and Levels of Oxidative Stress Markers in Patients with Rheumatoid Arthritis: the 52-Week Analysis
Hiroaki Niiro¹, Hiroshi Tsukamoto², Yojiro Arinobu², Mitsuteru Akahoshi², Hiroki Mitoma², Kensuke Oryoji³, Yasushi Inoue⁴, Takuya Sawabe⁵, Shuji Nagano⁶, Hiroaki Nishizaka⁷, Seiji Yoshizawa⁸, Yoshifumi Tada⁹, Shigeru Yoshizawa¹⁰, Takeshi Otsuka¹¹, Akira Ueda¹², Hitoshi Nakashima¹³, Takahiko Horiuchi¹⁴ and Koichi Akashi², ¹Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³The Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, ⁴Department of Rheumatology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ⁵Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan, ⁶Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁷Kitakyushu Municipal Medical Center, Kitakyushu, Japan, ⁸Hamanomachi Hospital, Fukuoka, Japan, ⁹Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ¹⁰Department of Rheumatology, Fukuoka Hospital, National Hospital Organization, Fukuoka, Japan, ¹¹Munakata Medical Association Hospital, Munakata, Japan, ¹²Department of Internal Medicine, Miyazaki Prefectural Hospital, Miyazaki, Japan, ¹³Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, ¹⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Despite their profound inhibitory effects on inflammation and bone destruction, it remains unclear whether biological therapies can improve the long-term prognosis of patients with…
Abstract Number: 1912 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency
Shunsuke Mori, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan
Background/Purpose: Renal involvement is relatively common in rheumatoid arthritis (RA) patients. Recent randomized controlled trials of anti-tumor necrosis factor-α (anti-TNFα) showed that the concomitant administration…
Abstract Number: 1906 • 2014 ACR/ARHP Annual Meeting
IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Atsuma Nishiwaki¹, Hitomi Kobayashi², Yasuyuki Kobayashi³, Isamu Yokoe¹, Noboru Kitamura², Hidetake Shiraiwa¹, Takamasa Nozaki¹, Hirotake Inomata², Natsumi Ikumi⁴, Kaita Sugiyama¹, Yousuke Nagasawa¹ and Masami Takei⁵, ¹Nihon University School of Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Dept of Med Rheumatology, Nihon University School of Medicine, Itabashi Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a 1.5–2.0 fold higher risk of developing congestive heart failure (CHF) than the general population. Small increases in…
Abstract Number: 1533 • 2014 ACR/ARHP Annual Meeting
Study of One Vial (400mg) per Body Infusion of Tocilizumab in Patients with Active Rheumatoid Arthritis
Hiroshi Uda¹, Koji Shigematsu² and Osamu Saiki¹, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: The treatment of active rheumatoid arthritis (RA) patients are usually started with synthetic disease modifying antirheumatic drugs (DMARDs), but when adequate response are not…
Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting
Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA
Kazuyuki Yoshizaki, Osaka University, Osaka, Japan
Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…
Abstract Number: 1179 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: Sequential Evaluation Using Whole-Body Magnetic Resonance Imaging
Michihito Kono¹, Shinsuke Yasuda¹, Kazumasa Ohmura¹, Tomoko Fukui¹, Sanae Shimamura¹, Ikuma Nakagawa¹, Atsushi Noguchi¹, Haruki Shida¹, Toshiyuki Watanabe¹, Yuka Shimizu¹, Takashi Kurita¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Keita Sakamoto², Tamotsu Kamishima³ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Hokkaido University, Faculty of Health Science, Sapporo, Japan
Background/Purpose: Magnetic Resonance Imaging (MRI) has been established as a useful modality to evaluate synovitis, bone edema, and bone erosion in patients with rheumatoid arthritis…
Abstract Number: 506 • 2014 ACR/ARHP Annual Meeting
Trial of Six Weeks Interval of Tocilizumab Infusion in Patients with Rheumatoid Arthritis
Osamu Saiki¹, Hiroshi Uda¹ and Koji Shigematsu², ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: For active rheumatoid arthritis (RA) patients with inadequate response to synthetic DMARDs, biologic agents, such as TNF inhibitor and IL-6 receptor inhibitor, are indicated.…
Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting
Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience
Francesca De Nard¹, Vittorio Grosso², Monica Todoerti³, Carlomaurizio Montecucco⁴ and Roberto Caporali⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, ³Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁵Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…
Abstract Number: 80 • 2014 ACR/ARHP Annual Meeting
Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry
Michael Kruse Meyer¹, Marlene Andersen², Grethe N. Andersen¹ and Allan Stensballe³, ¹Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, ²Department of Rheumatology, Aalborg University, Hjørring, Denmark, ³Health Science and Technology, Aalborg University, Aalborg, Denmark
Background/Purpose: In this study we are analyzing leukocyte subtype responses from patients with rheumatoid arthritis (RA) to IL6 inhibition. A large contribution to RA immunopathogenesis…
Abstract Number: 2506 • 2014 ACR/ARHP Annual Meeting
Decrease in the Number of Peripheral Leukocytes and Neutrophils and Increase of the Percentage of Eosinophils at 4 Week Predict the DAS28-ESR Remission at 24 Weeks after Administration of Tocilizumab
Tamao Nakashita¹, Shinji Motojima² and Akira Jibatake³, ¹[email protected], Kameda Medical Center, Kamogawa-city, Japan, ²[email protected], Kameda Medical Center, Kamogawa City, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose : Tocilizumab (TCZ) is a monoclonal anti-IL-6 receptor antibody, and is very effective in controlling RA activity. However we had noticed that the change…
Abstract Number: 2508 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients
Virginia Ruiz-Esquide¹, Azucena Gonzalez-Navarro², Jordi Yagüe³, Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Julio Ramirez¹, Sonia Cabrera-Villalba¹, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose Tocilizumab (TCZ) is a humanized monoclonal antibody against interleukin-6 receptor used for the treatment of active rheumatoid arthritis (RA). The response to this treatment…
Abstract Number: 2481 • 2014 ACR/ARHP Annual Meeting
Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with DMARDsÂ in Rheumatoid Arthritis Patients in a Real Life Setting?: An Interim Analysis of Safety and Efficacy at 6 Months
Jacques Tebib¹, Isabelle Idier², Mathieu Coudert³, David Pau⁴, Rene-Marc Flipo⁵ and Jean-Francis Maillefert⁶, ¹Rheumatology, University Hospital Lyon, Lyon, France, ²Chugai Pharma, La Defense, France, ³Statistics, Experis IT, Nanterre, France, ⁴Statistics, Roche, Boulogne-Billancourt, France, ⁵Rheumatology, University Hospital Lille, Lille, France, ⁶Rheumatology, University Hospital Dijon, Dijon, France
Background/Purpose Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].